iZumi Bio's Pact with Kyoto U May Help Bolster Firm's Position as Early Leader in iPSC Tech

Although iZumi does not have a license to Kyoto iPSC patents, the collaboration builds upon other seminal iPSC IP it recently licensed from Bayer. The Kyoto deal may also help the company better define iZumi's stake in what is shaping up to be a complicated IP landscape surrounding the technology.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.